RBC Life Sciences (RBCL) 0.7000 $RBCL
Chairman and Chief Executive Officer of RBC Life Sciences Addresses Company Performance
PR Newswire - Thu Jun 12, 4:00PM CDT
RBC Life Sciences, Inc. (OTCQB: RBCL), a provider of proprietary nutritional supplements, and wound care and pain management products, today released the following letter which was sent to the Company's stockholders addressing recent performance.
RBC Life Sciences ' net loss widens to USD500,000 in 2013
M2 - Fri Mar 28, 6:45AM CDT
Nutritional supplements company RBC Life Sciences (Other OTC:RBCL) stated on Thursday its net loss of USD500,000 (USD0.23 per diluted share) for the year ended 31 December 2013.
RBC Life Sciences Reports 2013 Results
PR Newswire - Thu Mar 27, 8:00AM CDT
RBC Life Sciences, Inc. (OTCQB: RBCL), a provider of proprietary nutritional supplements, and wound care and pain management products, today reported consolidated net sales of $25.5 million for the year ended December 31, 2013, a 1% increase over 2012 consolidated net sales of $25.2 million. For the year ended December 31, 2013, the Company reported a net loss of $500,000, or $0.23 per diluted share, compared to a net loss of $361,000, or $0.16 per diluted share, during 2012.
RBC Life Sciences Announces Share Repurchase Program
PR Newswire - Wed Aug 28, 7:00AM CDT
RBC Life Sciences, Inc. (OTCQB: RBCLD), a provider of proprietary nutritional supplements, and wound care and pain management products (the "Company"
, today announced that its Board of Directors approved a share repurchase program, authorizing the Company to repurchase in the aggregate up to 111,000 shares, representing 5% of the shares, of its currently outstanding common stock.
RBC Life Sciences Inc reports launch of reverse stock split & forward stock split
M2 - Mon Aug 12, 5:24AM CDT
Nutritional supplements company RBC Life Sciences Inc (RBCLD:OTC Markets) on Friday declared a one-for-500 reverse stock split of its common stock.
RBC Life Sciences Announces Stock Splits
PR Newswire - Fri Aug 09, 3:00PM CDT
RBC Life Sciences, Inc. (OTCQB: RBCL), a provider of proprietary nutritional supplements, and wound care and pain management products (the "Company" , today announced that it is effecting a 1-for-500 reverse stock split of the Company's Common Stock (the "Common Stock" , followed by a 50-for-1 forward stock split of the Common Stock (the "Stock Splits" as of the commencement of trading on the OTCQB on Monday, August 12, 2013. In addition, at the opening of the market on August 12, 2013, the Common Stock will trade under a new CUSIP number, 74926T 201. The Company's ticker symbol, RBCL, will be temporarily appended with a "D" for a period of 20 days to indicate the effectiveness of the Stock Splits.
RBC Life Sciences Reports Second Quarter Results
PR Newswire - Wed Aug 07, 1:00PM CDT
RBC Life Sciences, Inc. (OTCQB: RBCL), a provider of proprietary nutritional supplements, and wound care and pain management products, today reported consolidated net sales of $6.7 million for the second quarter of 2013, a 2% increase over the second quarter of 2012. For the second quarter of 2013, the Company reported a net loss of $147,000, or $0.01 per share, compared to net earnings of $320,000, or $0.01 per share, for the same quarter last year. Net sales were $12.4 million for the six months ended June 30, 2013, a 2% decrease over the same period in 2012. For the six months ended June 30, 2013, the Company reported a net loss of $155,000, or $0.01 per share, compared to net earnings of $247,000, or $0.01 per share for the comparable period in 2012.
RBC Life Sciences Reports First Quarter 2013 Results
PR Newswire - Wed May 15, 1:13PM CDT
RBC Life Sciences, Inc. (OTCQB: RBCL), a provider of proprietary nutritional supplements, and wound care and pain management products, today reported consolidated net sales of $5.7 million for the first quarter ended March 31, 2013, a 6% decrease over the first quarter ended March 31, 2012. For the first quarter of 2013, the Company reported a net loss of $8,000, or $0.00 per diluted share, compared to a net loss of $73,000, or $0.00 per diluted share, during the first quarter of 2012.
RBC Life Sciences wins US patent for Neurobright to improve cognitive function
M2 - Thu Jan 31, 9:17AM CST
Nutritional supplements company RBC Life Sciences Inc (OTC Markets:RBCL) reported on Wednesday the receipt of the US Patent 8357422 for its unique cognitive dietary supplement formulation, Neurobright.
US Patent Granted to RBC Life Sciences for Supplement that Supports Cognitive Function
PR Newswire - Wed Jan 30, 3:37PM CST
RBC Life Sciences, Inc. (OTCQB: RBCL) (the "Company" , has been granted US Patent 8357422, which protects its unique dietary supplement formulation that nutritionally supports cognitive function, learning and remembering. The Company markets this supplement under the name "Neurobright®." The grant of this patent evidences the Company's continued commitment to bring effective science-based dietary supplements to the market.
Chairman and Chief Executive Officer of RBC Life Sciences Addresses Company Performance
PR Newswire - Thu Jun 12, 4:00PM CDT
RBC Life Sciences, Inc. (OTCQB: RBCL), a provider of proprietary nutritional supplements, and wound care and pain management products, today released the following letter which was sent to the Company's stockholders addressing recent performance.
RBC Life Sciences ' net loss widens to USD500,000 in 2013
M2 - Fri Mar 28, 6:45AM CDT
Nutritional supplements company RBC Life Sciences (Other OTC:RBCL) stated on Thursday its net loss of USD500,000 (USD0.23 per diluted share) for the year ended 31 December 2013.
RBC Life Sciences Reports 2013 Results
PR Newswire - Thu Mar 27, 8:00AM CDT
RBC Life Sciences, Inc. (OTCQB: RBCL), a provider of proprietary nutritional supplements, and wound care and pain management products, today reported consolidated net sales of $25.5 million for the year ended December 31, 2013, a 1% increase over 2012 consolidated net sales of $25.2 million. For the year ended December 31, 2013, the Company reported a net loss of $500,000, or $0.23 per diluted share, compared to a net loss of $361,000, or $0.16 per diluted share, during 2012.
RBC Life Sciences Announces Share Repurchase Program
PR Newswire - Wed Aug 28, 7:00AM CDT
RBC Life Sciences, Inc. (OTCQB: RBCLD), a provider of proprietary nutritional supplements, and wound care and pain management products (the "Company"
, today announced that its Board of Directors approved a share repurchase program, authorizing the Company to repurchase in the aggregate up to 111,000 shares, representing 5% of the shares, of its currently outstanding common stock. RBC Life Sciences Inc reports launch of reverse stock split & forward stock split
M2 - Mon Aug 12, 5:24AM CDT
Nutritional supplements company RBC Life Sciences Inc (RBCLD:OTC Markets) on Friday declared a one-for-500 reverse stock split of its common stock.
RBC Life Sciences Announces Stock Splits
PR Newswire - Fri Aug 09, 3:00PM CDT
RBC Life Sciences, Inc. (OTCQB: RBCL), a provider of proprietary nutritional supplements, and wound care and pain management products (the "Company"
, today announced that it is effecting a 1-for-500 reverse stock split of the Company's Common Stock (the "Common Stock" , followed by a 50-for-1 forward stock split of the Common Stock (the "Stock Splits" as of the commencement of trading on the OTCQB on Monday, August 12, 2013. In addition, at the opening of the market on August 12, 2013, the Common Stock will trade under a new CUSIP number, 74926T 201. The Company's ticker symbol, RBCL, will be temporarily appended with a "D" for a period of 20 days to indicate the effectiveness of the Stock Splits. RBC Life Sciences Reports Second Quarter Results
PR Newswire - Wed Aug 07, 1:00PM CDT
RBC Life Sciences, Inc. (OTCQB: RBCL), a provider of proprietary nutritional supplements, and wound care and pain management products, today reported consolidated net sales of $6.7 million for the second quarter of 2013, a 2% increase over the second quarter of 2012. For the second quarter of 2013, the Company reported a net loss of $147,000, or $0.01 per share, compared to net earnings of $320,000, or $0.01 per share, for the same quarter last year. Net sales were $12.4 million for the six months ended June 30, 2013, a 2% decrease over the same period in 2012. For the six months ended June 30, 2013, the Company reported a net loss of $155,000, or $0.01 per share, compared to net earnings of $247,000, or $0.01 per share for the comparable period in 2012.
RBC Life Sciences Reports First Quarter 2013 Results
PR Newswire - Wed May 15, 1:13PM CDT
RBC Life Sciences, Inc. (OTCQB: RBCL), a provider of proprietary nutritional supplements, and wound care and pain management products, today reported consolidated net sales of $5.7 million for the first quarter ended March 31, 2013, a 6% decrease over the first quarter ended March 31, 2012. For the first quarter of 2013, the Company reported a net loss of $8,000, or $0.00 per diluted share, compared to a net loss of $73,000, or $0.00 per diluted share, during the first quarter of 2012.
RBC Life Sciences wins US patent for Neurobright to improve cognitive function
M2 - Thu Jan 31, 9:17AM CST
Nutritional supplements company RBC Life Sciences Inc (OTC Markets:RBCL) reported on Wednesday the receipt of the US Patent 8357422 for its unique cognitive dietary supplement formulation, Neurobright.
US Patent Granted to RBC Life Sciences for Supplement that Supports Cognitive Function
PR Newswire - Wed Jan 30, 3:37PM CST
RBC Life Sciences, Inc. (OTCQB: RBCL) (the "Company"
, has been granted US Patent 8357422, which protects its unique dietary supplement formulation that nutritionally supports cognitive function, learning and remembering. The Company markets this supplement under the name "Neurobright®." The grant of this patent evidences the Company's continued commitment to bring effective science-based dietary supplements to the market. 
